share_log

中國生物製藥：二零二四年中期報告

HKEX ·  Sep 26 16:30

Summary by Futu AI

中國生物製藥有限公司（「本公司」）公佈截至2024年6月30日止六個月的未經審核中期業績。期內，本公司收入達人民幣158.7億元，同比增長11.1%；歸屬於母公司持有者的盈利為人民幣30.2億元，同比大幅增加139.7%。基於歸屬於母公司持有者之經調整非《香港財務報告準則》歸母淨利潤計算之每股基本盈利為人民幣8.34分，同比增長15.0%。本公司董事會宣佈派發截至2024年6月30日止六個月之中期股息每股3港仙。本公司於開曼群島註冊成立，主要業務包括生產、銷售及配銷中藥現代製劑及西藥產品。本公司股份於香港聯合交易所有限公司主板上市。
中國生物製藥有限公司（「本公司」）公佈截至2024年6月30日止六個月的未經審核中期業績。期內，本公司收入達人民幣158.7億元，同比增長11.1%；歸屬於母公司持有者的盈利為人民幣30.2億元，同比大幅增加139.7%。基於歸屬於母公司持有者之經調整非《香港財務報告準則》歸母淨利潤計算之每股基本盈利為人民幣8.34分，同比增長15.0%。本公司董事會宣佈派發截至2024年6月30日止六個月之中期股息每股3港仙。本公司於開曼群島註冊成立，主要業務包括生產、銷售及配銷中藥現代製劑及西藥產品。本公司股份於香港聯合交易所有限公司主板上市。
Sino Biopharm Limited ("the Company") announced the unaudited interim results for the six months ended June 30, 2024. During the period, the Company's revenue reached RMB 15.87 billion, an 11.1% year-on-year increase; the profit attributable to owners of the parent company was RMB 3.02 billion, a significant 139.7% year-on-year increase. Based on the adjusted basic earnings per share attributable to owners of the parent company, calculated on a per share basis not in accordance with Hong Kong Financial Reporting Standards, the basic earnings per share were RMB 8.34, a 15.0% year-on-year increase. The Board of Directors of the Company announced a distribution of an interim dividend of HK 3 cents per share for the six months ended June 30, 2024. The Company is registered and established in the Cayman Islands, with main business activities including the production, sale, and distribution of modern traditional Chinese medicine and Western pharmaceutical products. The Company's shares are listed on the main board of the Hong Kong Stock Exchange.
Sino Biopharm Limited ("the Company") announced the unaudited interim results for the six months ended June 30, 2024. During the period, the Company's revenue reached RMB 15.87 billion, an 11.1% year-on-year increase; the profit attributable to owners of the parent company was RMB 3.02 billion, a significant 139.7% year-on-year increase. Based on the adjusted basic earnings per share attributable to owners of the parent company, calculated on a per share basis not in accordance with Hong Kong Financial Reporting Standards, the basic earnings per share were RMB 8.34, a 15.0% year-on-year increase. The Board of Directors of the Company announced a distribution of an interim dividend of HK 3 cents per share for the six months ended June 30, 2024. The Company is registered and established in the Cayman Islands, with main business activities including the production, sale, and distribution of modern traditional Chinese medicine and Western pharmaceutical products. The Company's shares are listed on the main board of the Hong Kong Stock Exchange.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated